The selective 5-HT2C receptor agonist lorcaserin entered clinical obesity trials with the
prevalent view that satiety was a primary mechanism of action. Subsequent Phase II and III …

Metabolic syndrome (MetS) is a cluster of metabolic risk factors associated with central
obesity, hyperglycemia, insulin resistance, dyslipidemia and high blood pressure. In recent …

Abstract Serotonin (5-hydroxytryptamine, 5-HT) is an important modulatory neurotransmitter
and functions as a key neurodevelopmental signal in the mammalian brain. 5-HT plays a …

Pramipexole and ropinirole are dopamine agonists that are efficacious in treating motor
disturbances of neuropathologies, eg, Parkinson's disease and restless legs syndrome. A …

There are no FDA‐approved treatments for cannabis use disorder (CUD). Preclinical
research has shown that the 5HT‐2C agonist lorcaserin attenuates cue‐induced …

Binge eating disorder (BED) is characterized by dysfunctional hedonic food intake and
reward-related processes. Activation of the serotonin (5-HT) 5-HT2C receptor (5-HT2CR) …

Cocaine use disorder is a serious public health issue for which there is no effective
pharmacotherapy. One strategy to speed development of medications for cocaine use …

Lorcaserin, a selective serotonin 2C (5-HT 2C) receptor agonist, was approved for treating
obesity and has been investigated for treating substance use disorders including those …

Abstract Serotonin2C receptor (5-HT 2C) agonists are promising drugs for the treatment of
neuropsychiatric diseases. However, their effect is not completely understood in part …

Nicotine addiction is a serious public health problem causing millions of deaths worldwide.
Serotonin (5-hydroxytryptamine; 5-HT) is involved in central nervous system (CNS) nicotine …